利妥昔单抗治疗原发性膜性肾病的研究进展  

Research Progress of Rituximab in the Treatment of Primary Membranous Nephropathy

作　　者：邢晖林 张娇 许清玉[1] 郭明好[1] XING Huilin;ZHANG Jiao;XU Qingyu;GUO Minghao(Nephrology Hospital,the First Affiliated Hospital of Xinxiang Medical University,Xinxiang 453100,China)

机构地区：[1]新乡医学院第一附属医院肾脏病医院,河南新乡453100

出　　处：《河南医学研究》2023年第2期376-380,共5页Henan Medical Research

摘　　要：随着对原发性膜性肾病(PMN)的免疫治疗方案不断探索,利妥昔单抗(RTX)的疗效与安全性得到了肯定。近年来国内外多项研究对比了RTX单药或联合其他免疫抑制剂治疗PMN的效果,但目前针对RTX治疗方案仍未达成一致。本文就RTX治疗PMN的方案、影响RTX治疗PMN效果的相关因素及RTX的不良反应进行综述。As immunotherapy options for primary membranous nephropathy(PMN)continue to be explored,the efficacy and safety of rituximab(RTX)have been confirmed.In recent years,several studies at home and abroad have compared the efficacy of RTX alone or in combination with other immunosuppressive agents in the treatment of PMN,but there is still no consensus on RTX treatment regimens.In this paper,the therapeutic regimen of RTX in the treatment of PMN,the related factors affecting the effect of RTX in the treatment of PMN and the adverse reactions of RTX were reviewed.

关 键 词：原发性膜性肾病 利妥昔单抗 磷脂酶A2受体 综述 

分 类 号：R692.6[医药卫生—泌尿科学]